Related Experiment Video

Updated: Oct 5, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Remission induced by a new specific oral polymeric diet in children with Crohn's disease

J M Fell1, M Paintin, A Donnet-Hughes

  • 1Chelsea and Westminster Hospital, London, UK.

Nestle Nutrition Workshop Series. Clinical & Performance Programme
|August 9, 2001
PubMed

Insights

CT3211 demonstrates effectiveness as an oral treatment for active Crohn's disease in children. This therapeutic approach was well-tolerated, showing significant mucosal improvement and reduced pro-inflammatory cytokines.

Area of Science:

  • Pediatric Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease is a chronic inflammatory bowel disease affecting children.
  • Current treatments for pediatric Crohn's disease have limitations.
  • Targeting pro-inflammatory cytokines is a key therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy and safety of CT3211 as an oral treatment for active Crohn's disease in pediatric patients.
  • To assess the impact of CT3211 on disease activity at the mucosal level.
  • To investigate the effect of CT3211 on pro-inflammatory cytokine expression.

Main Methods:

  • A study involving children with active Crohn's disease.
  • Administration of CT3211 as an oral therapy.
  • Assessment of macroscopic and histological disease improvement.
  • Measurement of pro-inflammatory cytokine levels (IL-1 beta, IL-8, IFN-gamma).

Main Results:

  • CT3211 proved to be an effective oral treatment for active pediatric Crohn's disease.
  • The treatment was well-tolerated with minimal adverse events.
  • Significant macroscopic and histological improvements were observed at the disease site.
  • Downregulation of pro-inflammatory cytokines, including IL-1 beta, IL-8, and IFN-gamma, was evident.

Conclusions:

  • CT3211 is a safe and effective oral therapeutic option for children with active Crohn's disease.
  • The drug's efficacy is supported by mucosal healing and modulation of inflammatory markers.
  • Further research into CT3211 for pediatric inflammatory bowel disease is warranted.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...